Abbott Laboratories (ABT) Stock Forecast & Price Target

$107.34 +2.85 (+2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$107.68 +0.34 (+0.32%)

As of 05:04 PM Eastern

Compare

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
3

Buy
22

Based on 26 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 3 have given a hold rating, 19 have given a buy rating, and 3 have given a strong buy rating for ABT.

Consensus Price Target

$118.17
10.09% Upside

According to the 26 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $118.17. The highest price target for ABT is $143.00, while the lowest price target for ABT is $92.00. The average price target represents a forecasted upside of 10.09% from the current price of $107.34.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Analyst Ratings Over Time

Type	Current Forecast 7/28/25 to 7/28/26	1 Month Ago 6/28/25 to 6/28/26	3 Months Ago 4/29/25 to 4/29/26	1 Year Ago 7/28/24 to 7/28/25
Strong Buy	3 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	19 Buy rating(s)	19 Buy rating(s)	19 Buy rating(s)	15 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$118.17	$118.30	$119.43	$145.22
Forecasted Upside	10.09% Upside	25.83% Upside	30.50% Upside	15.00% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	Broader Market
Consensus Rating Score	2.92	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	10.06% Upside	981.89% Upside	12.01% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/28/2026	UBS Group 4 of 5 stars	Patrick Wood Not Rated	Lower Target	Buy	$135.00 ➝ $125.00	+16.39%
7/23/2026	Weiss Ratings 5 of 5 stars		Downgrade	Hold (C-) ➝ Sell (D+)
7/17/2026	Citigroup 4 of 5 stars	Joanne Wuensch 2 of 5 stars	Boost Target	Buy	$108.00 ➝ $112.00	+12.14%
7/17/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$115.00 ➝ $118.00	+18.35%
7/17/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$110.00 ➝ $120.00	+18.76%
7/17/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$109.00 ➝ $112.00	+10.49%
7/17/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joshua Jennings Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$115.00	+13.70%
7/17/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$130.00	+31.57%
7/17/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$131.00 ➝ $134.00	+35.61%
7/1/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$121.00	+33.44%
Get the Latest News and Ratings for ABT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.
6/12/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$120.00 ➝ $102.00	+14.47%
5/27/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$121.00 ➝ $113.00	+30.87%
4/22/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$92.00	-0.89%
4/21/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$140.00 ➝ $125.00	+30.13%
4/21/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Market Perform	$119.00 ➝ $106.00	+10.35%
4/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$144.00 ➝ $143.00	+47.59%
4/17/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$125.00 ➝ $110.00	+15.70%
4/17/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$134.00 ➝ $120.00	+26.22%
4/17/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$130.00 ➝ $115.00	+20.96%
4/17/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$125.00 ➝ $115.00	+20.96%
4/17/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$145.00 ➝ $135.00	+41.99%
4/17/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$132.00 ➝ $115.00	+20.96%
4/17/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Jackson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$145.00 ➝ $120.00	+26.22%
4/17/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$145.00 ➝ $120.00	+26.22%
1/29/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
11/20/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lewis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$127.00 ➝ $137.00	+3.75%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:41 PM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 27, 2026. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

The current stock price is around $91, which may present a buying opportunity for investors looking for growth in the healthcare sector.
Abbott Laboratories has reported a strong quarterly revenue increase of 13.0% year-over-year, indicating robust business performance and potential for future growth.
The company has a solid dividend yield of approximately 2.4%, providing investors with a steady income stream in addition to potential capital appreciation.
With a return on equity of 17.65%, Abbott demonstrates effective management and profitability, which can be attractive to investors seeking reliable returns.
The company operates in diverse healthcare segments, including diagnostics and medical devices, which can help mitigate risks associated with market fluctuations.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

The payout ratio is currently at 81.55%, which may indicate that the company is returning a significant portion of its earnings to shareholders, potentially limiting funds available for reinvestment in growth opportunities.
Abbott's price-to-earnings ratio of 33.38 suggests that the stock may be overvalued compared to its earnings, which could pose a risk for new investors.
The company has a debt-to-equity ratio of 0.56, which, while manageable, indicates that Abbott is somewhat reliant on debt financing, potentially increasing financial risk.
Market analysts predict earnings per share of 5.51 for the current year, which may not meet investor expectations if growth slows.
Recent fluctuations in stock price could indicate volatility, which may deter risk-averse investors from committing to Abbott Laboratories.

ABT Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $118.17, with a high forecast of $143.00 and a low forecast of $92.00.

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There is currently 1 sell rating, 3 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABT shares.

According to analysts, Abbott Laboratories's stock has a predicted upside of 10.09% based on their 12-month stock forecasts.

Over the previous 90 days, Abbott Laboratories's stock had 2 upgrades and 2 downgrades by analysts.

Abbott Laboratories has been rated by research analysts at Bank of America, BTIG Research, Citigroup, JPMorgan Chase & Co., Piper Sandler, Robert W. Baird, Royal Bank Of Canada, TD Cowen, The Goldman Sachs Group, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abbott Laboratories Recommendations

This page (NYSE:ABT) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ABT Analyst Ratings Over Time

ABT Analyst Recommendations By Month

ABT Price Targets by Month

Abbott Laboratories Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

Abbott Laboratories
Bull Case

Abbott Laboratories
Bear Case

ABT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abbott Laboratories Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ABT Analyst Ratings Over Time

ABT Analyst Recommendations By Month

ABT Price Targets by Month

Abbott Laboratories Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

Abbott Laboratories Bull Case

Abbott Laboratories Bear Case

ABT Forecast - Frequently Asked Questions

What is Abbott Laboratories' forecast for 2026?

Should I buy or sell Abbott Laboratories stock right now?

Does Abbott Laboratories's stock price have much upside?

Has Abbott Laboratories been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Abbott Laboratories?

Do Wall Street analysts like Abbott Laboratories more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abbott Laboratories Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Abbott Laboratories
Bull Case

Abbott Laboratories
Bear Case